[1] Ishihara J, Fukunaga K, Ishihara A, Larsson HM, Potin L, Hosseinchi P, Galliverti G, Swartz MA, Hubbell JA. Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events. Sci Transl Med. 2017 Nov 8;9(415). pii: eaan0401. doi: 10.1126/scitranslmed.aan0401.
Home Ishihara J, Fukunaga K, Ishihara A
